Macrophages Effect on Chemoresistance

Impact of Macrophages on De-Novo Chemoresistance of Adenocarcinoma Cells

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01921699

Enrollment

Registered

2013-08-13

Start date

2013-08-31

Completion date

Unknown

Last updated

2013-08-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

the Focus of the Study is Macrophage-induced Chemoresistance in Pancreatic Carcinoma Cells During Chemotherapy.

Keywords

macrophages, adenocarcinoma, chemoresistance

Brief summary

Macrophages are derived from monocytes recruited to the tumor site and stimulated by specific chemokines secreted by tumor cells. These tumor associated macrophages (TAMs) have been postulated as being involved in the progression of cancer. Based on our preliminary findings and on published data we hypothesized that macrophage-induced chemoresistance (MIC) can promote survival of pancreatic carcinoma cells during chemotherapy. The overall goal of this study is to evaluate the mechanism of MIC in an in-vitro model of Pancreatic ductal adenocarcinoma (PDA). methods: 1. The human PDA cell line Panc1 will be grown in suitable conditions. 2. Macrophages will be produced by incubating mononuclear cells from the blood of healthy donors in medium with M-CSF for 7 days. 3. TAMs will be generated by culturing these macrophages with tumor-culture conditioning medium (TCCM) of PDA Cells for an additional 72 hours. 4. Human pancreatic cells (PANC1) will be treated with gemcitabine following exposure to macrophages CM. 5. Cell proliferation will be quantified by light microscopy and by an XTT Cell Proliferation Assay Kit.

Interventions

PROCEDUREtaking blood samples from healthy people

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

BASIC_SCIENCE

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 40 Years

Healthy volunteers

Yes

Inclusion criteria

* healthy people

Exclusion criteria

* refusal to participate

Design outcomes

Primary

Measure	Time frame	Description
proliferation and migration of PANC1 cell line in the tested groups.	one day to get the blood samples, and a year after that to complete the basic research	the macrophages will be isolated from the blood we'll get from the healthy volunteers. the outcome measure is related to the basic research and not clinical so there's no symptom/outcome related to the participants.

Secondary

Measure	Time frame
To determine whether direct cell-to-cell interaction or soluble factors participate in MIC.	a year from obtaining the blood samples

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026